Artiva reports AlloNK shows deep B-cell depletion in 32 autoimmune patients; FDA interaction planned 1H 2026

Artiva Biotherapeutics, Inc.

32 patients dosed with AlloNK + anti-CD20 mAb as outpatients at community rheumatology sites; no CRS, ICANS or GvHD.
No Grade 3+ AlloNK-related TEAEs, no discontinuations; only one hospitalization (unrelated skin infection).
All 23 analyzed patients had undetectable peripheral CD19+ B-cells by Day 13; high-sensitivity assay confirms depletion.
B-cell depletion depth comparable to CD19-auto-CAR-T, greater than rituximab alone per published studies.
Plans to share initial RA response data from >15 patients and align with FDA on pivotal trial design in 1H 2026.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.